Oleylethanolamide: A Novel Potential Pharmacological Alternative to Cannabinoid Antagonists for the Control of Appetite

Adele Romano, 1 Roberto Coccurello, 2 Giacomo Giacovazzo, 2 Gaurav Bedse, 1 Anna Moles, 2,3 and Silvana Gaetani 1

1 Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
2 Institute of Cell Biology and Neurobiology (IBCN), Italian National Research Council (CNR), Via del Fosso di Fiorano, 64-00146 Roma, Italy
3 Genomnia Srl, Via Nerviano 31, Lainate, 20020 Milano, Italy

Correspondence should be addressed to Roberto Coccurello; roberto.coccurello@cnr.it

Received 25 November 2013; Revised 18 February 2014; Accepted 5 March 2014; Published 3 April 2014

Academic Editor: Andrew J. McAinch

Copyright © 2014 Adele Romano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The initial pharmaceutical interest for the endocannabinoid system as a target for antiobesity therapies has been restricted by the severe adverse effects of the CB1 antagonist rimonabant. This study points at oleylethanolamide (OEA), a monounsaturated analogue, and functional antagonist of anandamide, as a potential and safer antiobesity alternative to CB1 antagonism. Mice treated with equal doses (5 or 10 mg/kg, i.p.) of OEA or rimonabant were analyzed for the progressive expression of spontaneous behaviors (eating, grooming, rearing, locomotion, and resting) occurring during the development of satiety, according to the paradigm called behavioral satiety sequence (BSS). Both drugs reduced food (wet mash) intake to a similar extent. OEA treatment decreased eating activity within the first 30 min and caused a temporary increase of resting time that was not accompanied by any decline of horizontal, vertical and total motor activity. Besides decreasing eating activity, rimonabant caused a marked increase of the time spent grooming and decreased horizontal motor activity, alterations that might be indicative of aversive nonmotivational effects on feeding. These results support the idea that OEA suppresses appetite by stimulating satiety and that its profile of action might be predictive of safer effects in humans as a novel antiobesity treatment.

1. Introduction

Despite the continuous increase of obesity incidence in all developed countries, limited pharmacological therapies are currently available to treat obesity in an efficacious and safe manner. Thus, development of effective and safe antiobesity therapies is a priority for both patients and health systems. Efficacy and safety are the ideal endpoints of antiobesity medications that should put together the ability to suppress food intake and reduce fat depots with the increase of nutrients oxidation and lack of major side effects burden. One of the most promising novel pharmacological targets for drug development is the endocannabinoid (EC) system and its related compounds, the N-acylethanolamines (NAEs).

Among the latter ones, anandamide represents the most studied compound mainly for its ability to act as endogenous ligand for cannabinoid receptor type 1 (CB1). A large body of evidence has clearly demonstrated that the stimulation of this receptor exerts powerful effects on energy balance, increasing appetitive drive and promoting adiposity [1, 2]. Therefore, several CB1 receptor antagonists have been tested in both genetic and dietary rodent models of obesity for their potential effects as antiobesity treatments [3–9]. One of these compounds, rimonabant (also referred as SR144716A) reached the market after successful clinical trials, which confirmed the observations made in rodents on its efficacy in body weight reduction and in the metabolic benefits induced in obese subjects [10, 11]. However, the emergence of severe
psychiatric adverse effects, mostly attributable to the inverse agonistic activity of rimonabant at central CB1 receptor, led to its withdrawal from the market [12, 13]. Such drawbacks led to a reassessment of the potential of the EC system as a drug target for novel antiobesity therapy aimed at preventing the severe side effects induced by central CB1 receptors blockade. Several reports have being indicating as possible safer pharmacological alternatives to rimonabant a number of novel “neutral” or “silent” CB1 receptor antagonists, such as AM4113, peripherally restricted CB1 receptor antagonists, such as AM6545, LH-21, MJ15, URB447 [14], CB1 receptor partial agonists, allosteric modulators of CB1 receptors, and other agents able to alter EC levels [15].

In this context, increasing interest has been focusing also on a group of NAEs that are AEA congeners but seem to act through mechanisms independent of CB1 receptors. This group includes the monounsaturated analogue oleyylethanolamide (OEA) [16, 17], which, although sharing similar biosynthetic pathways [18] with AEA, exerts opposite effects on feeding regulation and lipid metabolism. AEA binds with high affinity the CB1 [19] and its administration induce hyperphagia that can be attenuated or abolished by CB1 receptor blockade [20–23]. In contrast to AEA, OEA does not have any affinity for CB1 receptor and its systemic administration inhibits food consumption in rodents by delaying eating onset. Recent studies on the physiological role of OEA demonstrated that it may act as a gut-derived satiety factor (for review: [16, 17, 24, 25]). In particular, OEA is synthesized in the upper part of the small intestine, upon the absorption of lipids from the diet [26–28]. OEA binds with high affinity the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α) [29] to control the expression of several genes involved in fat absorption and fatty acid metabolism, to activate hypothalamic oxytocinergic neurons and to inhibit further eating [29–32]. These effects were observed in rodents when OEA was systemically administered at dosages ranging from 5 to 20 mg/kg [32, 33], with an ED50 = 9.2 ± 1.6 mg/kg, i.p. [34].

Accumulating evidence suggests that OEA might be involved in different pathophysiological aspects of appetite and metabolism regulation. For example, elevated OEA concentration has been described in plasma and cerebrospinal fluid of woman affected by eating disorders [35], in the saliva of obese subjects [36], and in the subcutaneous adipose tissue of subjects with both obesity and type 2 diabetes [37]. Conversely, decreased OEA intestinal content was observed in rodent models of obesity [38–40]. These findings might suggest that excessive or altered food intake may render the mechanism dysfunctional, raising the possibility that OEA might represent a novel pharmacological target to treat such pathologies. This hypothesis is supported by several observations made on obese rodent models in which OEA decreased hyperphagia and body weight gain, increased lipolysis, and decreased hypertriglyceridemia, hypercholesterolemia, and liver steatosis, when chronically administered thus demonstrating a significant effect not only on the acute, short-term—but also on the long-term appetite and energy regulation [31, 41–45]. Moreover, the link between dietary fat intake and OEA’s action on feeding behaviour and obesity has been recently strengthened by the finding that OEA subchronic treatment can reestablish a normal response of the brain reward system to an intraduodenal infusion of lipids that seems to be altered in diet-induced-obese mice [46]. Since similar reward hypofunctionality has been described in obese subjects and has been proposed as part of the central mechanism sustaining hyperphagia, this finding suggests a potential therapeutic relevance of OEA in food addiction [46]. Based on these considerations, in this study we propose OEA as a possible pharmacological alternative to anorexiant and/or antiobesity drugs targeting CB1 receptors. To test our hypothesis we compared the acute effects of OEA with those of rimonabant on spontaneous behaviors observed in mice during the beginning of the consummatory phase of their daily activities, as assessed in the paradigm of the behavioral satiety sequence (BSS).

The commonest dependent variable recorded in animal studies aimed at understanding drug effects on feeding is the amount of food eaten by the animals [47]. However, food intake and feeding behavior can be affected by several factors, including those acting in nonspecific manners, such as pain, stress, anxiety, and nausea. Therefore, one of the most contentious issues in the psychopharmacology of appetite regulation is the identification of the physiologic mechanisms underlying the observed reduction of eating. Animals cannot report their aversive side effects and the maintenance of a normal feeding structure in strings of behavioral acts may be used to verify drug effects on the normal physiology of appetite regulation. The BSS is an observational approach that allows investigating the effects of drugs acting on feeding by examining the presence of an orderly progression of behavioral patterns from eating to grooming and finally to resting, as it is typically observed in the rodent spontaneous behavior during the development of satiety [48, 49]. As previously underlined [50, 51], since the BSS relies on the animal’s spontaneous pattern of feeding, this paradigm helps to circumvent several problems of model validity associated to other testing procedures.

In previous studies, the analysis of BSS in rats treated with rimonabant has revealed that this compound preserves the order of events and, nevertheless, differs markedly from the natural satiation. The most notable difference is that grooming (particularly scratching) is profoundly enhanced at anorectic doses, while eating and resting are diminished, raising the possibility that anorectic effect is simply secondary to the grooming effect [50, 52]. Recent evidence does not appear to support this hypothesis, showing that the acute anorectic response induced by rimonabant cannot be just accounted by the time spent in grooming behavior [14, 53]. Moreover, excessive grooming in rodents may be indicative of an altered emotional state induced by rimonabant administration. This hypothesis has been confirmed by specific behavioral tests in rodents and by clinical observations showing that rimonabant is an anxiogenic compound [54, 55].

On the other hand, several clues suggest that the anorexiant actions of OEA are not attributable to stress or malaise. In fact, it has been shown that OEA does not elicit fear or anxiety-like behaviors, does not affect plasma corticosterone
levels, and does not induce conditioned taste aversion in rats [31]. Moreover, by the meal pattern analysis of animals subjected to the acute OEA treatment, we previously demonstrated that OEA selectively delays the normal eating onset in free-feeding rats and mice without affecting meal size and postmeal interval, suggesting that this lipid mediator may participate in the physiological control of satiety [32]. However, whether OEA can affect other spontaneous behaviors related to eating, such as those analyzed in the BSS paradigm, remained unexplored [33].

Therefore, in this study we evaluated the behavioral profile of mice that underwent acute administration with either OEA or rimonabant, by focusing on the occurrence of spontaneous behaviors typically investigated via the BSS paradigm. Per each compound we tested two different doses (i.e., 5 or 10 mg/kg, i.p.), based on the results of our previous acute dose-response studies [32–34] on OEA’s anorexiant effects. Both OEA doses were previously demonstrated to be sufficient to activate fully PPAR-α [29]. The dosages of rimonabant were chosen to obtain an acute inhibition of food intake in mice that could be similar to that elicited by OEA treatment. These doses are consistent with previous studies [4, 56–59] showing that they can lead to more than 95% of brain CB1 receptor occupancy [60].

2. Materials and Methods

2.1. Animals and Housing. All experiments were carried out on male C57BL6/J inbred mice that were generously provided by the CNR-EMMA animal facility (Monterotondo, Rome, Italy). Mice, 9-week-old, weighing 26 ± 0.5 g at the beginning of the experiments, were housed individually in breeding cages (26.7 × 20.7 × 14 cm) in a room with humidity control and constant temperature (22 ± 1°C) on a 12 h light/dark cycle (lights off 7:00 PM). Animals had ad libitum access to standard diet (4RF21; Mucedola s.r.l., Milan, Italy) and water. Thirty-eight C57BL6/J mice were used for the study of feeding behavior via the BSS protocol. Housing, animal maintenance, and all experiments were performed in accordance with the Council Directive of the European Community (86/EEC) of the Italian D.L. 116 (January 27, 1992) and approved by veterinarian supervision.

2.2. Drugs. N-Piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazolecarboxamide (rimonabant) and (9Z)-N-[(2-hydroxyethyl)octadec-9-enameide (OEA) were dissolved in 5% Tween—80/50% polyethylene glycol/saline (by volume) and injected intraperitoneally (i.p.) in a volume of 10 mL/kg of body weight. Rimonabant and OEA were purchased from Cayman Chemical (Ann Arbor, Michigan 48108, USA). All HPLC chemicals were from Sigma-Aldrich (Milan, Italy).

2.3. Habitation to Wet Mash. Before the start of BSS, mice were habituated for 10 days to the special diet used during the behavioral satiety sequence procedure (see below), which consists in a nonsweetened wet meal (i.e., wet mash, WM) that was always prepared fresh on a daily basis. In particular, wet mash was made up of a mixture of one-part ground standard dry powdered food pellets to 2.5 parts distilled water, during both habituation and BSS testing. Powdered food was obtained by the standard maintenance diet (4RF21 diet) that provides an energy value of 3.95 Kcal/g. The use of hydrated food or WM as test diet has been acknowledged in the BSS by several studies and procedures [61–63]. WM provides higher than standard diet palatability also in its nonsweetened form. The increase in palatability provides higher mean diet intake as compared to nonhydrated food and its consistency permits to minimize spillage, thus allowing a more accurate estimation of food intake. Although spillage is maximally curtailed by WM texture, its possible occurrence was always checked at the end of each observational period. WM was provided in small opaque plastic beakers (3 cm diameter) mounted on a plastic Petri dish [48], further reducing the possibility that WM is consumed in a different place. During the habituation phase, WM was offered for 2 h/day during daylight period (4:00–6:00 PM) up to the day before drug treatment and BSS testing. During the habituation to WM consumption, both body weight (g) and food intake (g) were measured daily (data not shown). The intake of wet mash was the difference between the weight of WM-containing food dispenser immediately before the meal presentation and the remaining food collected and recorded after 2 h. The BSS analysis was performed only in case WM daily consumption stabilized over the course of the habituation period, thus preventing the risk of neophobic reactions.

2.4. Drug Treatment and Behavioral Satiety Sequence (BSS). According to a former analytic description of the BSS procedure [51], all the behavioral patterns were monitored continuously and not coded or collected by a sampling technique. The duration (sec) of the behavioral patterns (i.e., time spent in a selected behavior) was recorded for each subject and separately scored, as follows: eating activity (mouse leaned on food dispenser biting, chewing, or holding food in paws), grooming (face and body cleansing, i.e., mouse scratching its face with its forepaws, licking or biting the coat), resting (total immobility), locomotion (horizontal motor activity), rearing (mouse completely erected on its hind legs), and total motor activity (horizontal activity and rearing). BSS-associated behaviors were recorded in animals’ home cages, thus avoiding the need of preliminary habituation to the testing environment to minimize novelty-induced anxiety. Trained observers blind to the experimental conditions performed the behavioral scoring. Mice were fasted for 12 h (08:00 AM–08:00 PM) and the evolution of BSS was recorded during the dark cycle (08:00 PM–09:00 PM) in a soundproof cubicle equipped with an infrared night-vision video recording camera (Panasonic color CCTV Camera WV-CP310/G). On the basis of a number of studies documenting the mean interval of satiety progression in rodents [48, 51, 64], the procedure was stopped after 45 min. This testing duration matches the time window described in the analysis of a typical BSS experimental protocol [62] that designates 40 min of feeding during the light-off phase as the time interval during which rodents ingest the most part of their daily food intake.
and the effects of anorectic agents can be better quantified. The testing duration of BSS is compatible with (i) the duration of OEA's anorexiant action that was previously reported to be evident for 1 h after treatment at the same doses used in the present study, (ii) the maximum plasma levels concentration of OEA (at either 5 mg/kg or 10 mg/kg) detected 30 min after its administration [32, 34, 65], and (iii) the in vivo half-life of 118.9 (±66.1) min of rimonabant, when administered at 1 mg/kg [66].

Immediately before wet mash presentation, mice were administered with one of the following treatments: OEA (either 5 or 10 mg/kg, i.p.; N = 8 and N = 8, resp.), rimonabant (either 5 or 10 mg/kg, i.p.; N = 8 and N = 8, resp.), or vehicle (10 mL/kg, i.p.; N = 6). Mice were given a preweighed amount of wet mash with the difference between initial and final weights corresponding to wet mash intake.

2.5. Data Analysis. Statistical analysis was performed using StatSoft, Inc. (2007) STATISTICA, version 8.0.

The total amount of wet mash consumed by animals during the 45 min observation period was analyzed by one-way ANOVA. The same statistical analysis was adopted to analyze the total duration of eating activity during the 45 min period. To analyze behavioral changes during the BSS, the 45 min continuous recording for each behavioral category was partitioned in 3 × 15 min time intervals. OEA and rimonabant effects on the duration of each BSS behavior were assessed by two-way repeated measures ANOVAs with treatment (5 levels, comprising two doses per drug and one vehicle group) as between-subject variable and time (3 levels, including 3 time intervals of 15 min each) as within-subject variable. All post hoc comparisons were carried out by Tukey HSD test. The criterion value for all statistical tests was P < 0.05.

3. Results

3.1. Effects of OEA and Rimonabant Administration on Wet Mash Intake and Time Spent Eating. The one-way ANOVA of the total amount of wet mash consumed showed a significant effect of treatment (F_{4,33} = 37.50, P < 0.0001). The post hoc analysis revealed that both drugs affected this parameter to a similar extent (Figure 1(a)). More specifically, a dose-dependent inhibition of mash intake was observed after OEA administration, while rimonabant treatment similarly inhibited feeding at both dosages (Figure 1(a)). Treatments affected also the total time spent eating, as revealed by the one-way ANOVA of the eating activity over the 45 min observation period (F_{4,33} = 30.09, P < 0.0001). The post hoc test demonstrated that both drugs at both dosages similarly affected this parameter (Figure 1(b)).

3.2. Effects of OEA and Rimonabant Administration on the Behavioral Satiety Sequence Pattern. Two-way ANOVA analysis revealed a significant treatment effect on eating activity (F_{4,33} = 30.09, P < 0.0001) during the 45 min BSS testing. A significant treatment × time interaction (F_{8,66} = 615.46, P < 0.00001) was also found. Post hoc comparisons revealed a significant decrease of eating activity (Figure 2(a)) in OEA (5 and 10 mg/kg; both P < 0.001) and rimonabant (5 and 10 mg/kg; both P < 0.001) groups, as compared to controls, at 15 and 30 min time intervals. The reduction in eating activity was still evident for rimonabant at 45 min at both doses (5 and 10 mg/kg; both P < 0.005). The ANOVA analysis demonstrated a significant treatment effect on grooming (F_{4,33} = 56.02, P < 0.0001) as well as a significant treatment × time interaction (F_{8,66} = 2.13, P < 0.05). Post-hoc comparisons showed that rimonabant significantly increased grooming at both doses (5 and 10 mg/kg; P < 0.001) whatever the time interval considered, while OEA.
never affected the total time spent in grooming activity (Figure 2(b)). Concerning the time spent in resting, two-way ANOVA analysis evidenced a significant treatment effect ($F_{4,33} = 5.73$, $P < 0.01$) and a significant treatment × time interaction ($F_{8,66} = 4.85$, $P < 0.0001$). As further revealed by the post hoc analysis, with the exception of a significant and temporary (present only at the second, 30 min, time interval) increase in the time spent in resting in animals treated with OEA (10 mg/kg), no other significant changes were detected (Figure 2(c)). Concerning locomotion (horizontal motor activity, Figure 2(d)), the ANOVA analysis disclosed a significant treatment effect ($F_{4,33} = 21.14$, $P < 0.0001$) and a significant treatment × time interaction ($F_{8,66} = 13.74$, $P < 0.0001$). Post hoc comparisons showed that horizontal motor activity was decreased at 15 min interval in animals administered with rimonabant (10 mg/kg; $P < 0.001$), after 30 min interval in animals that received both doses of rimonabant (5 and 10 mg/kg; $P < 0.01$ and $P < 0.005$, resp.), while no significant changes were detected at the last time interval considered (45 min, Figure 2(d)). Moreover, two-way ANOVA analysis showed a significant treatment effect on rearing ($F_{4,33} = 8.75$, $P < 0.0001$) and a significant treatment × time interaction ($F_{8,66} = 4.24$, $P < 0.001$). Post hoc analysis evidenced that none of the drugs studied significantly affected the rearing activity. As showed (Figure 2(e)), although there was a tendency for rimonabant (10 mg/kg) to reduce rearing this reduction did not result significant. Finally, the ANOVA analysis on the total motor activity (Figure 2(f)) evidenced a significant main treatment effect ($F_{4,33} = 22.64$, $P < 0.0001$) and a significant treatment × time interaction ($F_{8,66} = 4.64$, $P < 0.0001$). Post hoc comparisons further showed that rimonabant induced a clear tendency to reduce total motor activity during the first time interval that became significant during the first time interval (15 min; 10 mg/kg; $P < 0.01$). Such decrease of total motor activity was evidenced also for the lower dose of rimonabant in the second (30 min) time interval (5 mg/kg; $P < 0.01$) (Figure 2(f)), while none of the drugs tested affected the whole motricity at the final time interval (45 min) analyzed (Figure 2(f)).

4. Discussion

The main finding of this study is that systemic administration of the same dosages of OEA or rimonabant produces similar anorexiant effects but different effects on other spontaneous behaviors related to feeding, such as grooming and resting. These similarities and differences may be of therapeutic relevance, since they might suggest that OEA is a possible pharmacological alternative to the CB1 antagonism/inverse agonism that might be devoid of the adverse effects observed with rimonabant.

Specifically, our results demonstrate that both drugs significantly reduced wet mash intake to a similar extent, with a clear dose-response fashion for OEA. This decrease was due to an overall similar decrease of eating activity recorded in the 45 min observation period. However, at the same time, the two drugs differed for the effects on other behaviors analyzed. In particular, grooming behavior was significantly affected by rimonabant treatment that caused a marked increase of the time spent in grooming throughout the 45 min period of observation (Figure 2(b)). Thus, although for the OEA-mediated effects the decrease of eating activity was less persistent than rimonabant, the general increase in grooming induced by rimonabant was identified all over the 45 min and no differences in the whole eating activity between the two drugs were detected (Figure 1(b)). Moreover, the grooming increase was paralleled by a decrease of locomotion (Figure 2(d)) and general activity (Figure 2(f)) particularly evident in mice treated with the highest dose of rimonabant. OEA treatment, besides decreasing eating activity within the first 30 min of observation, caused also a delayed increase (evident at 30 min) of the time spent resting in mice treated with the highest dose (Figure 2(c)). However, such increase was not accompanied by any decrease of horizontal (locomotion), vertical (rearing), and total motor activity whatever the dose tested.

The effects of rimonabant on grooming behavior in rodents have been described in the literature with similar observations made also for the preclinical effects of other CB1 receptor antagonists/inverse agonists and even newer neutral CB1 receptor antagonists [50, 53]. In particular several studies described a syndrome of compulsive scratching and grooming in rodents as well as severe itching and scratching in humans [14, 67, 68]. Initially such effects were considered to be responsible for the anorexiant actions of the drugs, due to a sort of response competition between eating and grooming/scratching behaviors. However, it has been demonstrated that the two actions are independent and probably mediated by the interactions of rimonabant with different (central versus peripheral) receptors and the involvement also of other mechanisms such as the activation of opioid receptors [14].

In our study we did not focus on scratching behaviour but did record an intense compulsive grooming in mice treated with rimonabant that gave us the idea of a competitive behavior able to interfere with eating activity. However, testing this hypothesis was beyond the aim of our experiments.

Compulsive grooming in mice has an important ethological relevance. It is particularly sensitive to stress and might indicate an altered emotional reactivity of the animal [69]. The stimulation of grooming behavior caused by rimonabant treatment is compatible with its anxiogenic effects observed in several animal models [54]. By contrast, this effect was completely absent in animals treated with OEA. We previously demonstrated that OEA decreases food intake in free-feeding rodents by causing a dose-dependent delay in eating onset, which is not accompanied by changes in meal size or postmeal interval [32]. This delay cannot be attributed to motoric inhibition, because it occurs at doses of OEA (5–10 mg/kg) that have no effect on either locomotor activity in the open field test or operant responding for food [31]. Furthermore, the OEA-induced delay in feeding is unlikely to be caused by anxiety or malaise since OEA does not alter rodent performance in the elevated plus-maze test or produce conditioned taste aversion for saccharin [31].

OEA actions seem to be associated with the activation of PPAR-α receptors, as its anorexiant effects, as well as those
Figure 2: Panels illustrate the temporal development (duration of each behavior in sec) of eating (a), grooming (b), resting (c), horizontal motor activity (d), rearing activity (e), and total motor activity (f) in mice treated with vehicle, OEA 5 mg/kg i.p. (OEA 5), rimonabant 5 mg/kg i.p. (R 5), OEA 10 mg/kg i.p. (OEA 10), and rimonabant 10 mg/kg, i.p. (R 10). Represented on the x-axes are 3 time intervals of 15 min each for a total of 45 min of BSS analysis. Experiments were carried out during light-off period (08:00 PM-09:00 PM). *P < 0.05 versus vehicle group for each time interval (Tukey HSD test).
reported on the meal pattern, have not been observed in PPAR-α null mice [29]. Other possible receptors suggested to be involved in OEA’s actions are the capsaicin receptor TRPV1 and the G protein coupled receptor GPR119 [70–72]. However, the observation that genetic deletion of TRPV1 or GPR119 in mice does not prevent OEA anorexiant actions [41, 73], as observed in mice lacking PPAR-α receptors [29], strongly supports the hypothesis that PPAR-α receptors mediate OEA effects on feeding behaviour.

Peripheral rather than central PPAR-α receptors seem to be particularly involved. This hypothesis is supported by the observation that OEA anorexiant action is completely absent when peripheral sensory fibers are removed by capsaicin treatment, by surgical dissection or when the drug is injected into the brain ventricles [31]. However, OEA can still inhibit feeding when locally infused in the rat lateral hypothalamus [74] and OEA and PPAR-α can be found in the brain, where they play a role in the modulation of several functions including cognition [75] drug and food reward [46, 76] neuroprotection [77] and sleep-waking cycle [74]. Nevertheless, the finding that systemic administration of OEA is not followed by increased levels of the drug in the brain [78] suggests that peripheral and central compartments of OEA distribution are kept separated. This is presumably attributable to the high expression of its degrading enzyme, fatty acid amide hydrolase, in the blood-brain barrier [79].

The same enzyme is responsible also for the degradation of AEA, which in many of the cited functions of OEA may be seen as a functional antagonist. This is particularly evident for the modulation of food intake and lipid metabolism, for which AEA and OEA play two opposite roles: AEA stimulates appetite and promotes lipogenesis and body weight gain, while OEA inhibits appetite, stimulates lipolysis, and decreases body weight gain.

5. Conclusions

Based on these considerations, the results of the present study corroborate the idea that OEA [24, 25, 80] might represent a novel anorexiant agent sharing with rimonabant similar powerful effects on food intake but not the same impact on feeding behavior. In contrast to rimonabant, OEA does not block CB1 receptors and is not accountable for the wide spectrum of unwanted effects typically observed with CB1 antagonists/reverse agonists, whereas, by acting as a functional antagonist, it might counteract the actions of ECs on appetite stimulation and on the control of energy balance. We have recently showed that OEA administration can induce satiety by indirectly stimulating oxytocin neurosecretion from the hypothalamus [30, 81, 82], thus further supporting the notion that OEA or OEA-related compounds might represent a novel and safer antiobesity agent [83, 84] targeting systems other than those controlled by CB1 activation/blockade.

Conflict of Interests

The authors declare no competing financial interests in relation to the work described.

Acknowledgments

The authors gratefully acknowledge the C.N.R.-E.M.M.A. animal research facility (Monterotondo, Rome, Italy). This research was supported by the Italian Ministry for Education, University and Research, (PRIN 2009ESX7T3 and FIR RBFR12DELS_003) that had no further role in study design; in the collection, analysis, and interpretation of data, in the writing of the report; and in the decision to submit the paper for publication. Anna Moles and Silvana Gaetani are equal senior authors.

References

[1] D. Cota, G. Marsicano, M. Tschop et al., “The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis,” The Journal of Clinical Investigation, vol. 112, no. 3, pp. 423–431, 2003.
[2] I. Mattias, T. Bisogno, and V. di Marzo, “Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake,” International Journal of Obesity, vol. 30, supplement 1, pp. S7–S12, 2006.
[3] A. L. Hildebrandt, D. M. Kelly-Sullivan, and S. C. Black, “Antiobesity effects of chronic cannabinoid CB2 receptor antagonist treatment in diet-induced obese mice,” European Journal of Pharmacology, vol. 462, no. 1–3, pp. 125–132, 2003.
[4] C. Ravinet Trillou, M. Arnone, C. Delorge et al., “Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 284, no. 2, pp. R345–R353, 2003.
[5] S. P. Vickers, L. J. Webster, A. Wyatt, C. T. Dourish, and G. A. Kennett, “Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats,” Psychopharmacology, vol. 167, no. 1, pp. 103–111, 2003.
[6] Z. D. Thornton-Jones, G. A. Kennett, K. R. Benwell et al., “The cannabinoid CB2 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake,” Pharmacology Biochemistry and Behavior, vol. 84, no. 2, pp. 353–359, 2006.
[7] M. Gary-Bobo, G. Elachouri, J. F. Gallas et al., “Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats,” Hepatology, vol. 46, no. 1, pp. 122–129, 2007.
[8] G. Riedel, P. Fadda, S. McKillop-Smith, R. G. Pertwee, B. Platt, and L. Robinson, “Synthetic and plant-derived cannabinoid receptor antagonists show hypoglycic properties in fasted and non-fasted mice,” British Journal of Pharmacology, vol. 156, no. 7, pp. 1154–1166, 2009.
[9] J. Tam, V. K. Vemuri, J. Liu et al., “Peripheral CB2 cannabinoid receptor blockade improves cardiometabolic risk in obese Zucker rats,” The Journal of Clinical Investigation, vol. 120, no. 8, pp. 2953–2969, 2010.
[10] L. F. van Gaal, A. M. Rissanen, A. J. Scheen, O. Ziegler, and S. Rossner, “Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk in overweight patients: 1-year experience from the RIO-Europe study,” The Lancet, vol. 365, no. 9468, pp. 1389–1397, 2005.
[11] F. X. Pi-Sunyer, L. J. Aronne, H. M. Heshmati, J. Devin, and J. Rosenstock, “Effect of rimonabant, a cannabinoid-1
receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial,” *The Journal of the American Medical Association*, vol. 295, no. 7, pp. 761–775, 2006.

[12] R. Christensen, P. K. Kristensen, E. M. Bartels, H. Bliddal, and A. Astrup, “Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials,” *The Lancet*, vol. 370, no. 9600, pp. 1706–1713, 2007.

[13] F. D. Christopoulos and D. N. Kiortsis, “An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 36, no. 1, pp. 10–18, 2011.

[14] F. L. Wright and R. J. Rodgers, “Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats,” *Psychopharmacology*, vol. 226, no. 2, pp. 415–431, 2013.

[15] F. J. Bermudez-Silva, M. P. Viveros, J. M. McPartland, and F. Rodriguez de Fonseca, “The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?” *Pharmacology Biochemistry and Behavior*, vol. 95, no. 4, pp. 375–382, 2010.

[16] P. Dipasquale, A. Romano, S. Cianci, L. Righetti, and S. Gaetani, “Oleoylethanolamide: a new player in energy metabolism control. Role in food intake,” *Drug Discovery Today: Disease Mechanisms*, vol. 7, no. 3-4, pp. e169–e174, 2010.

[17] D. Piomelli, “A fatty gut feeling,” *Trends in Endocrinology & Metabolism*, vol. 24, no. 7, pp. 332–341, 2013.

[18] Y. Okamoto, J. Morishita, K. Tsuboi, T. Tonai, and N. Ueda, “Molecular characterization of a phospholipase D generating anandamide and its congeners,” *The Journal of Biological Chemistry*, vol. 279, no. 7, pp. 5298–5305, 2004.

[19] V. M. Showalter, D. R. Compton, B. R. Martin, and M. E. Abood, “Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2) : identification of cannabinoid receptor subtype selective ligands,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 278, no. 3, pp. 989–999, 1996.

[20] C. M. Williams and T. C. Kirkham, “Anandamide induces overeating: mediation by central cannabinoid (CB2) receptors,” *Psychopharmacology*, vol. 143, no. 3, pp. 315–317, 1999.

[21] C. Reyes-Cabello, F. Alen, R. Gomez et al., “Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration,” *Pharmacology Biochemistry and Behavior*, vol. 101, no. 1, pp. 1–7, 2012.

[22] N. Jamshidi and D. A. Taylor, “Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats,” *British Journal of Pharmacology*, vol. 134, no. 6, pp. 1151–1154, 2001.

[23] R. Gomez, M. Navarro, B. Ferrer et al., “A peripheral mechanism for CB2 cannabinoid receptor-dependent modulation of feeding,” *The Journal of Neuroscience*, vol. 22, no. 21, pp. 9612–9617, 2002.

[24] H. S. Hansen and T. A. Diep, “N-acylethanolamines, anandamide and food intake,” *Biochemical Pharmacology*, vol. 78, no. 6, pp. 553–560, 2009.

[25] A. Sarro-Ramirez, D. Sanchez-Lopez, A. Tejeda-Padron, C. Frias, J. Zaldivar-Rae, and E. Murillo-Rodriguez, “Brain molecules and appetite: the case of oleoylethanolamide,” *Central Nervous System Agents in Medicinal Chemistry*, vol. 13, no. 1, pp. 88–91, 2013.

[26] J. Fu, G. Astarita, S. Gaetani et al., “Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine,” *The Journal of Biological Chemistry*, vol. 282, no. 2, pp. 1518–1528, 2007.

[27] G. J. Schwartz, J. Fu, G. Astarita et al., “The lipid messenger OEA links dietary fat intake to satiety,” *Cell Metabolism*, vol. 8, no. 4, pp. 281–288, 2008.

[28] J. Fu, N. V. Dipatrizio, A. Guijarro et al., “Sympathetic activity controls fat-induced oleoylethanolamide signaling in small intestine,” *The Journal of Neuroscience*, vol. 31, no. 15, pp. 5730–5736, 2011.

[29] J. Fu, S. Gaetani, F. Oveisi et al., “Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α,” *Nature*, vol. 425, pp. 90–93, 2003.

[30] S. Gaetani, J. Fu, T. Cassano et al., “The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin,” *The Journal of Neuroscience*, vol. 30, no. 24, pp. 8096–8101, 2010.

[31] F. Rodriguez de Fonseca, M. Navarro, R. Gomez et al., “An anorexic lipid mediator regulated by feeding,” *Nature*, vol. 414, no. 6860, pp. 209–212, 2001.

[32] S. Gaetani, F. Oveisi, and D. Piomelli, “Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide,” *Neuropsychopharmacology*, vol. 28, no. 7, pp. 1311–1316, 2003.

[33] F. Oveisi, S. Gaetani, K. T. Eng, and D. Piomelli, “Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration,” *Pharmacological Research*, vol. 49, no. 5, pp. 461–466, 2004.

[34] G. Astarita, B. di Giacomo, S. Gaetani et al., “Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 318, no. 2, pp. 563–570, 2006.

[35] S. Gaetani, W. H. Kaye, V. Cuomo, and D. Piomelli, “Role of endocannabinoids and their analogues in obesity and eating disorders,” *Eating and Weight Disorders*, vol. 13, no. 3, pp. e42–e48, 2008.

[36] I. Matias, B. Gatta-Cherifi, A. Tabarin et al., “Endocannabinoids measurement in human saliva as potential biomarker of obesity,” *PLoS ONE*, vol. 7, no. 7, article e42399, 2012.

[37] G. Annuzzi, F. Piscitelli, L. di Marino et al., “Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients,” *Lipids in Health and Disease*, vol. 9, article 43, 2010.

[38] A. Artmann, G. Petersen, L. I. Hellgren et al., “Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine,” *Biochimica et Biophysica Acta*, vol. 1781, no. 4, pp. 200–212, 2008.

[39] G. Aviello, I. Matias, R. Capasso et al., “Inhibitory effect of the anorexopic compound oleoylethanolamide on gastric emptying in control and overweight mice,” *Journal of Molecular Medicine*, vol. 86, no. 4, pp. 413–422, 2008.

[40] T. A. Diep, A. N. Madsen, B. Holst et al., “Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor,” *The FASEB Journal*, vol. 25, no. 2, pp. 765–774, 2011.

[41] J. Ilo Verme, S. Gaetani, J. Fu, F. Oveisi, K. Burton, and D. Piomelli, “Regulation of food intake by oleoylethanolamide,” *Cellular and Molecular Life Sciences*, vol. 62, no. 6, pp. 708–716, 2005.

[42] J. Fu, F. Oveisi, S. Gaetani, E. Lin, and D. Piomelli, “Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats,” *Neuropsychopharmacology*, vol. 48, no. 8, pp. 1147–1153, 2005.
[43] E. P. Newberry, S. M. Kennedy, Y. Xie et al., “Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp−/− mice,” *Journal of Lipid Research*, vol. 53, no. 4, pp. 744–754, 2012.

[44] C. Thabuis, F. Destaillets, J.-F. Landrier, D. Tissot-Favre, and J.-C. Martin, “Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice,” *The Journal of Nutritional Biochemistry*, vol. 21, no. 10, pp. 922–928, 2010.

[45] A. Serrano, I. del Arco, F. Javier Pavon, M. Macias, V. Perez-Valero, and F. Rodriguez de Fonseca, “The cannabinoid CB1 receptor antagonist SR141716A (rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats,” *Neuropharmacology*, vol. 54, no. 1, pp. 226–234, 2008.

[46] L. A. Tellez, S. Medina, W. Han et al., “A gut lipid messenger links excess dietary fat to dopamine deficiency,” *Science*, vol. 341, no. 6147, pp. 800–802, 2013.

[47] K. L. Ellacott, G. J. Morton, S. C. Woods, P. Tso, and M. W. Schwartz, “Assessment of feeding behavior in laboratory mice,” *Cell Metabolism*, vol. 12, no. 1, pp. 10–17, 2010.

[48] R. Coccurello, A. Caprioli, S. Bellantuono et al., “Effects of the increase in neuronal fatty acids availability on food intake and satiety in mice,” *Psychopharmacology*, vol. 210, no. 1, pp. 85–95, 2010.

[49] R. Coccurello, F. R. D’Amato, and A. Moles, “Chronic administration of olanzapine affects Behavioral Satiety Sequence and motor activity,” in *American Journal of Physiology: Regulatory Integrative and Comparative Physiology*, vol. 289, no. 3, pp. R729–R737, 2005.

[50] A. J. Tallett, J. E. Blundell, and R. J. Rodgers, “Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats,” *Psychopharmacology*, vol. 195, no. 1, pp. 27–39, 2007.

[51] J. C. Halford, S. C. Wanninayake, and J. E. Blundell, “Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake,” *Pharmacology Biochemistry and Behavior*, vol. 61, no. 2, pp. 159–168, 1998.

[52] R. J. Rodgers, P. Holch, and A. J. Tallett, “Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite,” *Psychopharmacology Biochemistry and Behavior*, vol. 97, no. 1, pp. 3–14, 2010.

[53] J. E. Schlosburg, S. T. O’Neal, D. H. Conrad, and A. H. Lichtman, “CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action,” *Psychopharmacology*, vol. 216, no. 3, pp. 323–331, 2011.

[54] A. V. Kalueff and P. Tuohimaa, “Mouse grooming microstructure is a reliable anxiety marker bidirectionally sensitive to GABAergic drugs,” *European Journal of Pharmacology*, vol. 508, no. 1–3, pp. 133–138, 2005.

[55] W. Han, D. Tissot-Favre, and J.-C. Martin, “Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice,” *The Journal of Nutritional Biochemistry*, vol. 21, no. 10, pp. 922–928, 2010.

[56] G. L. Gessa, A. Orru, P. Lai et al., “Decreased suppressive effect of rimonabant on chocolate intake in rhesus monkeys,” *Psychopharmacology*, vol. 185, no. 2, pp. 248–254, 2006.

[57] E. B. Rasmussen, W. Reilly, J. Buckley, and S. R. Boomhower, “Rimonabant reduces the essential value of food in the genetically obese Zucker rat: an exponential demand analysis,” *Physiology and Behavior*, vol. 105, no. 3, pp. 734–741, 2012.
secretion from the intestinal enteroendocrine L-cell,” *Diabetes*, vol. 58, no. 5, pp. 1058–1066, 2009.

[73] H. Lan, G. Vassileva, A. Corona et al., “GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis,” *Journal of Endocrinology*, vol. 201, no. 2, pp. 219–230, 2009.

[74] E. Soria-Gomez, K. Guzman, O. Pech-Rueda, C. J. Montes-Rodriguez, M. Cisneros, and O. Prospero-Garcia, “Oleoylthanolamide affects food intake and sleep-waking cycle through a hypothalamic modulation,” *Pharmacological Research*, vol. 61, no. 5, pp. 379–384, 2010.

[75] P. Campolongo, B. Roozendaal, V. Trezza et al., “Fat-induced satiety factor oleoylthanolamide enhances memory consolidation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 19, pp. 8027–8031, 2009.

[76] M. Melis, G. Pilolla, A. Luchicchi et al., “Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors,” *The Journal of Neuroscience*, vol. 28, no. 51, pp. 13985–13994, 2008.

[77] B. Galan-Rodriguez, J. Suarez, R. Gonzalez-Aparicio et al., “Oleoylthanolamide exerts partial and dose-dependent neuro-protection of substantia nigra dopamine neurons,” *Neuropharmacology*, vol. 56, no. 3, pp. 653–664, 2009.

[78] J. Fu, J. Kim, F. Oveis, G. Astarita, and D. Piomelli, “Targeted enhancement of oleoylthanolamide production in proximal small intestine induces across-meal satiety in rats,” *American Journal of Physiology: Regulatory Integrative and Comparative Physiology*, vol. 295, no. 1, pp. R45–R50, 2008.

[79] M. Egertova, B. F. Cravatt, and M. R. Elphick, “Fatty acid amide hydrolase expression in rat choroid plexus: possible role in regulation of the sleep-inducing action of oleamide,” *Neuroscience Letters*, vol. 282, no. 1-2, pp. 13–16, 2000.

[80] A. Serrano, F. J. Pavon, S. Tovar et al., “Oleoylthanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake,” *Neuropharmacology*, vol. 60, no. 4, pp. 593–601, 2011.

[81] A. Romano, T. Cassano, B. Tempesta et al., “The satiety signal oleoylthanolamide stimulates oxytocin neurosecretion from rat hypothalamic neurons,” *Peptides*, vol. 49, pp. 21–26, 2013.

[82] A. Romano, C. S. Potes, B. Tempesta et al., “Hindbrain noradrenergic input to the hypothalamic PVN mediates the activation of oxytocinergic neurons induced by the satiety factor oleoylthanolamide,” *American Journal of Physiology: Endocrinology and Metabolism*, vol. 305, no. 10, pp. E1266–E1273, 2013.

[83] J. M. Decara, M. Romero-Cuevas, P. Rivera et al., “Elaidylsulfamide, an oleoylthanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats,” *Disease Models & Mechanisms*, vol. 5, no. 5, pp. 660–670, 2012.

[84] J. Suarez, P. Rivera, S. Arrabal et al., “Oleoylthanolamide enhances beta-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat,” *Disease Models & Mechanisms*, vol. 7, no. 1, pp. 129–141, 2014.